Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Splenic marginal zone lymphoma.

Vito Franco1, Ada Maria Florena, Emilio Iannitto

  • 1Istituto di Anatomia e Istologia Patologica and Divisione di Ematologia con TMO, University of Palermo, Palermo, Italy. vfranco@unipa.it

Blood
|November 26, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Histiocytic myocarditis: A rare and complex cause of cardiogenic shock.

Legal medicine (Tokyo, Japan)·2026
Same author

Real-Time Gastric Juice Analysis in Cirrhotic Patients: Can We Avoid Unrewarding Gastric Biopsies?

GE Portuguese journal of gastroenterology·2025
Same author

<i>Erratum</i> to: Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study.

Haematologica·2025
Same author

Laryngeal Frame Involvement as The First Sign of Wegener's Granulomatosis.

Iranian journal of otorhinolaryngology·2025
Same author

Successful Treatment with Patisiran in Amyloid Polyneuropathy Harboring His90Asn Mutation in the <i>TTR</i> Gene.

Brain sciences·2024
Same author

Delayed Traumatic Rupture of the Spleen in a Patient with Mantle Cell Non-Hodgkin Lymphoma after an In-Hospital Fall: A Fatal Case.

Diagnostics (Basel, Switzerland)·2024

Splenic marginal zone lymphoma (SMZL) is a low-grade B-cell cancer characterized by splenomegaly and an indolent course. Research highlights diagnostic challenges and varied therapeutic options for this rare condition.

Area of Science:

  • Hematology
  • Oncology
  • Pathology

Background:

  • Splenic marginal zone lymphoma (SMZL) is a distinct low-grade small B-cell lymphoma.
  • It is characterized by splenomegaly, lymphocytosis with villous morphology, and organ involvement.
  • While often indolent, a minority of patients experience tumor progression and aggressive behavior.

Purpose of the Study:

  • To review the diagnostic features and challenges of SMZL.
  • To discuss the current understanding of molecular and cytogenetic findings.
  • To outline established and potential therapeutic strategies for SMZL.

Main Methods:

  • Review of World Health Organization classification criteria for SMZL.
  • Analysis of clinical, morphological, and pathological features.

Related Experiment Videos

  • Summary of molecular, cytogenetic, and therapeutic data from existing literature.

    • Main Results:

    • SMZL presents with characteristic splenomegaly and specific blood/bone marrow findings.
    • Diagnostic criteria can be challenging, leading to heterogeneous molecular and cytogenetic results.
    • Therapeutic options are varied and include observation, splenectomy, radiation, and chemotherapy.

    Conclusions:

    • SMZL is a unique entity within B-cell lymphomas requiring careful diagnosis.
    • Further standardization in diagnostic criteria may improve understanding of its molecular landscape.
    • No single definitive therapy exists, necessitating individualized treatment approaches.